"Imagine if sm1 gets some legs and turns out to be a success like sm6.
Sm6 is such a tiny market in comparison to sm1.
Sm6 = 450,000 new cases of blood cancer each year sm1 = 22,000 new cased (from memory) of MM.
Potentially HUGE !!!!"
Gregl84,
SM6 scope is so much wider than simply multiple melanoma but PAB have made a very clever and well thought move in targeting MM in this trial.
Firstly there is the niche field for MM where they can clearly see the gap that exists and the competitive nature amongst the companies targeting this space. With the high toxicity profiles of current drugs either in market or in clinic pushing SM6 through with it's squeaky clean profile folds right in.
Secondly being a rare disease with significantly unmet solutions allows the company the opportunity to expedite the development process with things such as Orphan Status as opposed to targeting other conditions that wont offer the same opportunities. A big assumption but assuming it gets to market it will be in a much shorter time frame whilst gaining incentives along the way & it is also then a much simpler and shorter path for an already approved drug to be stamped forward for other diseases.
SM6 was shown preclinical to bind to multiple different cancers - melanoma, breast, colon, pancreatic etc. Just because the current trial is targeting multiple melanoma don't assume that is the only condition it will be applicable to over time.
FWIW SM6 binds to GRP78 protein whilst LM1 attacks NONO so while some of the same diseases may be targeted by each compound the method by which they act is different.
PAB Price at posting:
5.1¢ Sentiment: None Disclosure: Held
